Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia

Risks and Benefits Up to 9 Years of Treatment

Martin H. Steinberg, Franca Barton, Oswaldo Castro, Charles H. Pegelow, Samir K. Ballas, Abdullah Kutlar, Eugene Orringer, Rita Bellevue, Nancy Olivieri, James Eckman, Mala Varma, Gloria Ramirez, Brian Adler, Wally Smith, Timothy Carlos, Kenneth Ataga, Laura DeCastro, Carolyn Bigelow, Yogen Saunthararajah, Margaret Telfer & 7 others Elliott Vichinsky, Susan Claster, Susan Shurin, Kenneth Bridges, Myron Waclawiw, Duane Bonds, Michael Terrin

Research output: Contribution to journalArticle

587 Citations (Scopus)

Abstract

Context: Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. Objective: To determine whether hydroxyurea attenuates mortality in patients with SCA. Design: Long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine if hydroxyurea reduces vaso-occlusive events. In the MSH Patients' Follow-up, conducted in 1996-2001, patients could continue, stop, or start hydroxyurea. Data were collected during the trial and in the follow-up period. Setting: Inpatients and outpatients in 21 sickle cell referral centers in the United States and Canada. Patients: Two-hundred ninety-nine adult patients with frequent painful episodes enrolled in the follow-up. Follow-up data through May 2001 were complete for 233 patients. Intervention: In the MSH, patients were randomly assigned to receive hydroxyurea (n=152) or placebo (n=147). Main Outcome Measures: Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts, The randomized trial was not designed to detect specified differences in mortality. Results: Seventy-five of the original 299 patients died, 28% from pulmonary disease. Patients with reticulocyte counts less than 250000/mm3 and hemoglobin levels lower than 9 g/dL had increased mortality (P=.002). Cumulative mortality at 9 years was 28% when HbF levels were lower than 0.5 g/ dL after the trial was completed compared with 15% when HbF levels were 0.5 g/ dL or higher (P=.03). Individuals who had acute chest syndrome during the trial had 32% mortality compared with 18% of individuals without acute chest syndrome (P=.02). Patients with 3 or more painful episodes per year during the trial had 27% mortality compared with 17% of patients with less frequent episodes (P=.06). Taking hydroxyurea was associated with a 40% reduction in mortality (P=.04) in this observational follow-up with self-selected treatment. There were 3 cases of cancer, 1 fatal. Conclusions: Adult patients taking hydroxyurea for frequent painful sickle cell episodes appear to have reduced mortality after 9 of years follow-up. Survival was related to HbF levels and frequency of vaso-occlusive events. Whether indications for hydroxyurea treatment should be expanded is unknown.

Original languageEnglish (US)
Pages (from-to)1645-1651
Number of pages7
JournalJournal of the American Medical Association
Volume289
Issue number13
DOIs
StatePublished - Apr 2 2003

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Morbidity
Mortality
Acute Chest Syndrome
Melanocyte-Stimulating Hormones
Therapeutics
Placebos
Reticulocyte Count
Fetal Hemoglobin
Blood Cell Count
Lung Diseases
Multicenter Studies
Canada
Inpatients

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia : Risks and Benefits Up to 9 Years of Treatment. / Steinberg, Martin H.; Barton, Franca; Castro, Oswaldo; Pegelow, Charles H.; Ballas, Samir K.; Kutlar, Abdullah; Orringer, Eugene; Bellevue, Rita; Olivieri, Nancy; Eckman, James; Varma, Mala; Ramirez, Gloria; Adler, Brian; Smith, Wally; Carlos, Timothy; Ataga, Kenneth; DeCastro, Laura; Bigelow, Carolyn; Saunthararajah, Yogen; Telfer, Margaret; Vichinsky, Elliott; Claster, Susan; Shurin, Susan; Bridges, Kenneth; Waclawiw, Myron; Bonds, Duane; Terrin, Michael.

In: Journal of the American Medical Association, Vol. 289, No. 13, 02.04.2003, p. 1645-1651.

Research output: Contribution to journalArticle

Steinberg, MH, Barton, F, Castro, O, Pegelow, CH, Ballas, SK, Kutlar, A, Orringer, E, Bellevue, R, Olivieri, N, Eckman, J, Varma, M, Ramirez, G, Adler, B, Smith, W, Carlos, T, Ataga, K, DeCastro, L, Bigelow, C, Saunthararajah, Y, Telfer, M, Vichinsky, E, Claster, S, Shurin, S, Bridges, K, Waclawiw, M, Bonds, D & Terrin, M 2003, 'Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment', Journal of the American Medical Association, vol. 289, no. 13, pp. 1645-1651. https://doi.org/10.1001/jama.289.13.1645
Steinberg, Martin H. ; Barton, Franca ; Castro, Oswaldo ; Pegelow, Charles H. ; Ballas, Samir K. ; Kutlar, Abdullah ; Orringer, Eugene ; Bellevue, Rita ; Olivieri, Nancy ; Eckman, James ; Varma, Mala ; Ramirez, Gloria ; Adler, Brian ; Smith, Wally ; Carlos, Timothy ; Ataga, Kenneth ; DeCastro, Laura ; Bigelow, Carolyn ; Saunthararajah, Yogen ; Telfer, Margaret ; Vichinsky, Elliott ; Claster, Susan ; Shurin, Susan ; Bridges, Kenneth ; Waclawiw, Myron ; Bonds, Duane ; Terrin, Michael. / Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia : Risks and Benefits Up to 9 Years of Treatment. In: Journal of the American Medical Association. 2003 ; Vol. 289, No. 13. pp. 1645-1651.
@article{5faf722bbceb46778514870ae9d70962,
title = "Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment",
abstract = "Context: Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. Objective: To determine whether hydroxyurea attenuates mortality in patients with SCA. Design: Long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine if hydroxyurea reduces vaso-occlusive events. In the MSH Patients' Follow-up, conducted in 1996-2001, patients could continue, stop, or start hydroxyurea. Data were collected during the trial and in the follow-up period. Setting: Inpatients and outpatients in 21 sickle cell referral centers in the United States and Canada. Patients: Two-hundred ninety-nine adult patients with frequent painful episodes enrolled in the follow-up. Follow-up data through May 2001 were complete for 233 patients. Intervention: In the MSH, patients were randomly assigned to receive hydroxyurea (n=152) or placebo (n=147). Main Outcome Measures: Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts, The randomized trial was not designed to detect specified differences in mortality. Results: Seventy-five of the original 299 patients died, 28{\%} from pulmonary disease. Patients with reticulocyte counts less than 250000/mm3 and hemoglobin levels lower than 9 g/dL had increased mortality (P=.002). Cumulative mortality at 9 years was 28{\%} when HbF levels were lower than 0.5 g/ dL after the trial was completed compared with 15{\%} when HbF levels were 0.5 g/ dL or higher (P=.03). Individuals who had acute chest syndrome during the trial had 32{\%} mortality compared with 18{\%} of individuals without acute chest syndrome (P=.02). Patients with 3 or more painful episodes per year during the trial had 27{\%} mortality compared with 17{\%} of patients with less frequent episodes (P=.06). Taking hydroxyurea was associated with a 40{\%} reduction in mortality (P=.04) in this observational follow-up with self-selected treatment. There were 3 cases of cancer, 1 fatal. Conclusions: Adult patients taking hydroxyurea for frequent painful sickle cell episodes appear to have reduced mortality after 9 of years follow-up. Survival was related to HbF levels and frequency of vaso-occlusive events. Whether indications for hydroxyurea treatment should be expanded is unknown.",
author = "Steinberg, {Martin H.} and Franca Barton and Oswaldo Castro and Pegelow, {Charles H.} and Ballas, {Samir K.} and Abdullah Kutlar and Eugene Orringer and Rita Bellevue and Nancy Olivieri and James Eckman and Mala Varma and Gloria Ramirez and Brian Adler and Wally Smith and Timothy Carlos and Kenneth Ataga and Laura DeCastro and Carolyn Bigelow and Yogen Saunthararajah and Margaret Telfer and Elliott Vichinsky and Susan Claster and Susan Shurin and Kenneth Bridges and Myron Waclawiw and Duane Bonds and Michael Terrin",
year = "2003",
month = "4",
day = "2",
doi = "10.1001/jama.289.13.1645",
language = "English (US)",
volume = "289",
pages = "1645--1651",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "13",

}

TY - JOUR

T1 - Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia

T2 - Risks and Benefits Up to 9 Years of Treatment

AU - Steinberg, Martin H.

AU - Barton, Franca

AU - Castro, Oswaldo

AU - Pegelow, Charles H.

AU - Ballas, Samir K.

AU - Kutlar, Abdullah

AU - Orringer, Eugene

AU - Bellevue, Rita

AU - Olivieri, Nancy

AU - Eckman, James

AU - Varma, Mala

AU - Ramirez, Gloria

AU - Adler, Brian

AU - Smith, Wally

AU - Carlos, Timothy

AU - Ataga, Kenneth

AU - DeCastro, Laura

AU - Bigelow, Carolyn

AU - Saunthararajah, Yogen

AU - Telfer, Margaret

AU - Vichinsky, Elliott

AU - Claster, Susan

AU - Shurin, Susan

AU - Bridges, Kenneth

AU - Waclawiw, Myron

AU - Bonds, Duane

AU - Terrin, Michael

PY - 2003/4/2

Y1 - 2003/4/2

N2 - Context: Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. Objective: To determine whether hydroxyurea attenuates mortality in patients with SCA. Design: Long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine if hydroxyurea reduces vaso-occlusive events. In the MSH Patients' Follow-up, conducted in 1996-2001, patients could continue, stop, or start hydroxyurea. Data were collected during the trial and in the follow-up period. Setting: Inpatients and outpatients in 21 sickle cell referral centers in the United States and Canada. Patients: Two-hundred ninety-nine adult patients with frequent painful episodes enrolled in the follow-up. Follow-up data through May 2001 were complete for 233 patients. Intervention: In the MSH, patients were randomly assigned to receive hydroxyurea (n=152) or placebo (n=147). Main Outcome Measures: Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts, The randomized trial was not designed to detect specified differences in mortality. Results: Seventy-five of the original 299 patients died, 28% from pulmonary disease. Patients with reticulocyte counts less than 250000/mm3 and hemoglobin levels lower than 9 g/dL had increased mortality (P=.002). Cumulative mortality at 9 years was 28% when HbF levels were lower than 0.5 g/ dL after the trial was completed compared with 15% when HbF levels were 0.5 g/ dL or higher (P=.03). Individuals who had acute chest syndrome during the trial had 32% mortality compared with 18% of individuals without acute chest syndrome (P=.02). Patients with 3 or more painful episodes per year during the trial had 27% mortality compared with 17% of patients with less frequent episodes (P=.06). Taking hydroxyurea was associated with a 40% reduction in mortality (P=.04) in this observational follow-up with self-selected treatment. There were 3 cases of cancer, 1 fatal. Conclusions: Adult patients taking hydroxyurea for frequent painful sickle cell episodes appear to have reduced mortality after 9 of years follow-up. Survival was related to HbF levels and frequency of vaso-occlusive events. Whether indications for hydroxyurea treatment should be expanded is unknown.

AB - Context: Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. Objective: To determine whether hydroxyurea attenuates mortality in patients with SCA. Design: Long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine if hydroxyurea reduces vaso-occlusive events. In the MSH Patients' Follow-up, conducted in 1996-2001, patients could continue, stop, or start hydroxyurea. Data were collected during the trial and in the follow-up period. Setting: Inpatients and outpatients in 21 sickle cell referral centers in the United States and Canada. Patients: Two-hundred ninety-nine adult patients with frequent painful episodes enrolled in the follow-up. Follow-up data through May 2001 were complete for 233 patients. Intervention: In the MSH, patients were randomly assigned to receive hydroxyurea (n=152) or placebo (n=147). Main Outcome Measures: Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts, The randomized trial was not designed to detect specified differences in mortality. Results: Seventy-five of the original 299 patients died, 28% from pulmonary disease. Patients with reticulocyte counts less than 250000/mm3 and hemoglobin levels lower than 9 g/dL had increased mortality (P=.002). Cumulative mortality at 9 years was 28% when HbF levels were lower than 0.5 g/ dL after the trial was completed compared with 15% when HbF levels were 0.5 g/ dL or higher (P=.03). Individuals who had acute chest syndrome during the trial had 32% mortality compared with 18% of individuals without acute chest syndrome (P=.02). Patients with 3 or more painful episodes per year during the trial had 27% mortality compared with 17% of patients with less frequent episodes (P=.06). Taking hydroxyurea was associated with a 40% reduction in mortality (P=.04) in this observational follow-up with self-selected treatment. There were 3 cases of cancer, 1 fatal. Conclusions: Adult patients taking hydroxyurea for frequent painful sickle cell episodes appear to have reduced mortality after 9 of years follow-up. Survival was related to HbF levels and frequency of vaso-occlusive events. Whether indications for hydroxyurea treatment should be expanded is unknown.

UR - http://www.scopus.com/inward/record.url?scp=0037414164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037414164&partnerID=8YFLogxK

U2 - 10.1001/jama.289.13.1645

DO - 10.1001/jama.289.13.1645

M3 - Article

VL - 289

SP - 1645

EP - 1651

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 13

ER -